Skip to main content

Advertisement

SpringerLink
Log in

Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Metastatic breast cancer as initial onset represents between 20 and 30 % of cases and is considered an incurable disease. The goal of its treatment is palliative, looking for increasing the survival while reducing the symptoms. Maintenance chemotherapy studies for metastatic breast cancer have demonstrated to prolong the progression-free survival, with unclear results in terms of overall survival. The main objectives of our study were the progression-free survival and overall survival in patients with recurring or metastatic breast cancer treated with capecitabine in the maintenance chemotherapy setting compared with patients not receiving maintenance chemotherapy. As secondary objectives, the frequency of dose-limiting toxicities and response rate were determined. A non-probabilistic sampling was used, through expert selection of patients from the recurring/metastatic breast cancer survey cared within the period from January 1, 2007, to December 21, 2012. A total of 77 patients were included. Clinical data of advanced/recurrent breast cancer patients that were treated with capecitabine were recorded. The study achieved its primary objective, since the progression-free survival was prolonged for the maintenance therapy group: 6.6 versus 18.1 months, p < 0.001. The absolute benefit was 11.5 months. Likewise, there was a benefit in the overall survival of 21.03 versus 29 months, p = 0.015, with an absolute benefit of 7.97 months. The toxicity profile was favorable in the maintenance group. The maintenance chemotherapy with capecitabine in patients treated at the National Medical Center Siglo XXI Oncology Hospital extends the overall survival and progression-free survival with a good toxicity profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. El Shagir N, Tfayli A, Hatoum H, Nachef Z, Dinh P, et al. Treatment of metastatic breast cáncer: state of the art subtypes and perspectives. Crit Rev Oncol Hematol. 2011;80:433–49.

    Article  Google Scholar 

  2. Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, et al. Impact on survival of early detection of isolated breast recurrences after primary treatment for breast cáncer: a meta analysis. Breast Cancer Res Treat. 2009;114:403–12.

    Article  CAS  PubMed  Google Scholar 

  3. Sanphner T, Tormey DC, Gray R. Annual hazard rates of recurrences for breast cáncer after primary therapy. J Clin Oncol. 1996;14:2738–46.

    Google Scholar 

  4. Fernandez Y, Cueva J, Palomo AG, Ramos M, De Juan A, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev. 2010;36:33–42.

    Article  CAS  PubMed  Google Scholar 

  5. Lv YG, Yu F, Yao Q, Chen JH, Wang L, et al. The role of surviving in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis. 2010;2:100–10.

    PubMed Central  CAS  PubMed  Google Scholar 

  6. Tkaczuk KH. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther. 2009;31:2273–9.

    Article  PubMed  Google Scholar 

  7. Cardoso F, Bedard PL, Winer EP, Pasani O, Senkus-konefka E, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single agent chemotherapy. J Natl Cancer Inst. 2009;101:1174–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Miles D, Von Minckwitz G, Seidman AD. Combination vs sequential single agent therapy in metastatic breast cancer. Oncologist. 2002;7:13–9.

    CAS  PubMed  Google Scholar 

  9. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, et al. Single agent vs combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;2:CD003372.

    PubMed  Google Scholar 

  10. Sanchez Muñoz A, Perez-Ruiz E, Ribelles N, Marquez A, Alba E. Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther. 2008;12:1907–12.

    Article  Google Scholar 

  11. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–5.

    CAS  PubMed  Google Scholar 

  12. Wagstaff A, Ibbotson T, Goa K. Capecitabine, a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003;63:217–36.

    Article  CAS  PubMed  Google Scholar 

  13. Tarbot DC, Moiseyenko V, Van Belle S, et al. Randomised phase II trial comparing oral capecitabine with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer. 2002;86:1367–72.

    Article  Google Scholar 

  14. Blum JL, Jones SE, Budzar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485–93.

    CAS  PubMed  Google Scholar 

  15. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759–68.

    Article  CAS  PubMed  Google Scholar 

  16. Cervantes G, Torrecillas L, Erazo AA, et al. Capecitabine as treatment after failure to taxanes for metastatic breast cancer. Proc Am Soc Clin Oncol. 2000;19:121.

    Google Scholar 

  17. Fumoleau P, Largillier R, Trillet-Lenoir V, et al. Capecitabine in patients with advanced breast cancer previously treated with anthracyclines and taxanes: results of large phase II study. Proc Am Soc Clin Oncol. 2002;21:62.

    Google Scholar 

  18. Jakob A, Bokemeyer C, Knop S, et al. Capecitabine in patients with breast cancer relapsing after high dose chemotherapy plus autologous peripheral stem cell transplantation, a phase II study. Anticancer Drugs. 2002;13:405–10.

    Article  CAS  PubMed  Google Scholar 

  19. Reichardt P, Von Minckwitz G, Lück HJ, et al. Capecitabine the new standard in metastatic breast cancer failing anthracycline and taxane containing chemotherapy? Mature results of a large multicenter phase II trial. EJC. 2001;37:191.

    Article  Google Scholar 

  20. Wong ZW, Wong KK, Chew L et al. Capecitabine as an oral chemotherapy agent in the treatment of refractory metastatic breast cancer. 36th annual meeting of the American Society of Clinical Oncology 2000;19:20.

  21. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812–23.

    Article  PubMed  Google Scholar 

  22. Thomas ES, Gomez HL, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–7.

    Article  CAS  PubMed  Google Scholar 

  23. Sparano JA, Vrdoljak E, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with anthracycline and a taxane. J Clin Oncol. 2010;28:3256–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. O’Shaughnessy J, Blum J, Moiseyenko V, et al. Randomized open label, phase II trial of oral capecitabine versus a reference arm of intravenous CMF as first line therapy for advanced/metastatic breast cancer. Ann Oncol. 2001;12:1247–54.

    Article  Google Scholar 

  25. Meza LA, Amin B, Horsey M et al. A phase II study of capecitabine in combination with paclitaxel as first of second line therapy in patients with metastatic breast cancer. 37th annual meeting of the American Society of Clinical Oncology 2001;20:70.

  26. Venturini M, Catzeddu T, Durando A, et al. A multicenter phase II study of TEX regimen (Taxotere, Epirubicin, and Xeloda) as first line treatment in advanced breast cancer. Ann Oncol. 2001;4:25.

    Google Scholar 

  27. Kattan J, Ghosn M, Farhat F, et al. Phase II study of vinorelbine and capecitabine combination as first line treatment of metastatic breast cancer. Ann Oncol. 2002;5:56.

    Google Scholar 

  28. Xu L, Song S, Zhu J, et al. Capecitabine + Trastuzumab as first line treatment in patients with Her 2 positive metastatic breast cancer: a phase II trial results. Breast Cancer Res Treat. 2006;100:s102.

    Google Scholar 

  29. Yamamoto D, Iwase S, Kitamura K, et al. A phase II study of trastuzumab and capecitabine for patients with Her 2- overexpressing metastatic breast cancer: Japan breast cancer research network (JBCRN) 00 trial. Cancer Chemother Pharmacol. 2008;61:509–14.

    Article  CAS  PubMed  Google Scholar 

  30. Wardley A, Antón-Torres A, Pivot X et al. Trastuzumab plus docetaxel with or without capecitabine as firts line therapy for Her 2-positive locally advanced or metastatic breast cancer: a randomised phase II study. Eur J Cancer Suppl. 2008;109:abstract 209.

  31. Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2 positive advanced breast cancer: a German breast group 26/breast international group 03–05 study. J Clin Oncol. 2009;27:1999–2006.

    Article  Google Scholar 

  32. Geyer CE, Foster J, Lindquist D, et al. Lapatinib plus capecitabine for Her 2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.

    Article  CAS  PubMed  Google Scholar 

  33. Gray R, Bhattacharya S, Bowden C, Miller K, Comis R, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27:4966–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Miles D, Chan A, Dirix L, Cortés J, Pivot X, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first line treatment of human epidermal growth factor negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–47.

    Article  CAS  PubMed  Google Scholar 

  35. Robert N, Dieras V, Glaspy J, Brufsky A, Bondarenko I, et al. RIBBON-1: randomized, double blind, placebo-controlled, phase III trial chemotherapy with or without bevacizumab for first line treatment of human epidermal growth factor receptor 2 negative locally, recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.

    Article  CAS  PubMed  Google Scholar 

  36. Brofsky A, Hurvitz S, Perez E, Swamy R, Valero V, et al. RIBBON-2: a randomized, double blind, placebo controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second line treatment of human epidermal gorwth factor receptor 2 negative metastatic breast cancer. J Clin Oncol. 2011;29:4286–93.

    Article  Google Scholar 

  37. Huang H, Jiang Z, Wang T, Zhang S, Bian L, et al. Single agent capecitabine maintenance therapy after response to capecitabine based combination chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 2012;23:718–23.

    Article  CAS  PubMed  Google Scholar 

  38. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 3.2012.

  39. Cortes J, OShaughnessy J, Loesch D, Blum J, Vahdat LT, et al. Eribulin monotherapy versus treatment of physician choice in patientes with metastatic breast cancer: a phase 3 open label randomised study. Lancet. 2011;377:914–23.

    Article  CAS  PubMed  Google Scholar 

  40. Gennari A, Stockler M, Pontoni M, Sormani M, Nanni O, et al. Duration of chemotherapy for metastatic breast cancer: A systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29:2144–9.

    Article  PubMed  Google Scholar 

  41. Muss H, Case LD, Richards F, White D, Cooper R, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med. 1991;325:1342–8.

    Article  CAS  PubMed  Google Scholar 

  42. Coates A, Stockler M, Wilcken N, et al. Controversies in metastatic breast cancer: optimal duration of CT. Am Soc Clin Oncol Educ Book. 2003;119–21.

  43. Alba E, Ruiz-Borrego M, Margelí M, Rodríguez-Lescure A, Sánchez-Rovira P, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat. 2010;122:169–76.

    Article  CAS  PubMed  Google Scholar 

  44. Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, et al. Lack of benefit of maintenance paclitaxel in first line chemotherapy in metastatic breast cancer. J Clin Oncol. 2006;24:3912–8.

    Article  CAS  PubMed  Google Scholar 

  45. Dufresne A, Pivot X, Tournigand C, Facchini T, Alweeg T, et al. Maintenance hormonal treatment improves progression free survival after first line chemotherapy in patients with metastatic breast cancer. Int J Med Sci. 2008;5:100–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Fabi A, Russillo M, Ferratti G, Metro G, Nistico C, et al. Maintenance bevacizumab beyond first line paclitaxel plus bevacizumab in patients with Her 2 negative, hormone receptor positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer. 2012;12:1–7.

    Article  Google Scholar 

  47. Bisagni G, Musolino M, Panebianco M, De Matties F, Nuzzo F, et al. The breast Avastin trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first line treatment of patients with locally recurrent or metastatic breast cancer. Cancer Chemother Pharmacol. 2013;71:1051–7.

    Article  CAS  PubMed  Google Scholar 

  48. Goldhirsch A, Winer EP, Wood W, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Experto Consensus of primary therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2203–23.

    Article  Google Scholar 

  49. Von Minckwitz G, Untch M, Blohmer J, Costa S, Eidtmann W, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to sincerely thank to Dr. Juan A. Silva, for their contribution drafting and revising the article critically for important intellectual content.

Conflict of interest

The authors indicated no potential conflict of interests.

Author information

Authors and Affiliations

  1. Instituto Nacional de Cancerología (INCan), San Fernando # 22, Col. Sección XVI, Tlalpan, C.P. 14080, Mexico City, Mexico

    Manuel Segura-González

  2. Hospital de Oncología, Centro Médico Nacional Siglo XXI, Avenida Cuauhtémoc 330, Doctores, 06720, Mexico City, D.F., Mexico

    Manuel Segura-González & Miguel Quintana-Quintana

Authors
  1. Manuel Segura-González
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miguel Quintana-Quintana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manuel Segura-González.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Segura-González, M., Quintana-Quintana, M. Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute. Med Oncol 32, 93 (2015). https://doi.org/10.1007/s12032-015-0533-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-015-0533-y

Keywords

Search

Navigation